Research & Development

Opposition Leader Urges Faster Vaccine Production at Dei BioPharma Inspection
Research & Development Opposition Leader Urges Faster Vaccine Production at Dei BioPharma Inspection

Uganda’s Leader of Opposition, Joel Ssenyonyi, alongside a group of 15 other Members of Parliament, recently conducted an insightful inspection of the Dei BioPharma facility located in Matugga. This visit, which took place on September 19, 2024, marked a significant milestone that underscored the f

Kaida BioPharma Enhances Social Media Presence to Combat Cancer
Research & Development Kaida BioPharma Enhances Social Media Presence to Combat Cancer

Kaida BioPharma, an emerging pharmaceutical company based in Fort Lauderdale, Florida, has announced the launch of its new corporate social media channels. This significant development aims to enhance the company’s presence across various platforms, including X, LinkedIn, and Facebook. By l

FDA Approves Kisqali Expanding Breast Cancer Treatment Options Over Verzenio
Research & Development FDA Approves Kisqali Expanding Breast Cancer Treatment Options Over Verzenio

In a significant move likely to reshape the competitive landscape, the FDA has granted approval for Novartis’ Kisqali, when paired with an aromatase inhibitor, for the adjuvant treatment of HR-positive, HER2-negative stage 2 and 3 breast cancer at high risk of recurrence post-surgery. This approval

Can GC Therapeutics' TFome Platform Revolutionize Cell Therapy?
Research & Development Can GC Therapeutics' TFome Platform Revolutionize Cell Therapy?

GC Therapeutics (GCTx), a biotech company founded in 2019, has captured the spotlight with its pioneering approach to cell therapy. With a mission centered on advanced induced pluripotent stem cell (iPSC)-based medicines, GCTx is driven by its innovative TFome platform. Bolstered by a successful

Ascendis Trials Shake Up the Market for Achondroplasia Treatments
Research & Development Ascendis Trials Shake Up the Market for Achondroplasia Treatments

The competitive landscape of pharmaceutical treatments for achondroplasia, a common cause of dwarfism, is experiencing a seismic shift, thanks to the recent clinical trial results from Ascendis Pharma. BioMarin Pharmaceutical, a long-time player in this niche market, finds itself under significant

Can MinervaX and Wacker Biotech Transform GBS Prevention?
Research & Development Can MinervaX and Wacker Biotech Transform GBS Prevention?

In a significant move for maternal and neonatal healthcare, Danish biotech company MinervaX has teamed up with German CDMO Wacker Biotech to develop a groundbreaking prophylactic vaccine for Group B Streptococcus (GBS) infections. This partnership marks a pivotal step in addressing a critical unmet

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later